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ifi ed by coating the surface of the adsorbent in CF-X with 
2-methacryloyloxyethyl phosphorylcholine (MPC), was 
also tested for its cytokine adsorptive property.  Results: 
The adsorbent in CF-X  showed a signifi cantly higher ad-
sorption rate for TNF-  , interleukin (IL)-6 and IL-10 com-
pared with other adsorbents (p  ! 0.05). Adsorbent in 
 Lixelle ®  showed good affi nity to TNF-  and IL-8. Espe-
cially, the adsorbent in CF-X almost completely removed 
TNF-  , whereas it also had considerable affi nity to nor-
mal IgG. MPCF-X showed decreased affi nity to IgG with 
considerable adsorptive properties to cytokines.  Conclu-
sion: Selective cytokine adsorption columns could be 
developed with improvement of currently available ad-
sorbents. Such a new selective cytokine adsorption col-
umn could be clinically applied for the treatment of SIRS/
sepsis. 
 Copyright © 2004 S. Karger AG, Basel 
 Introduction 
 Sepsis is deﬁ ned as systemic inﬂ ammatory response 
syndrome (SIRS) caused by infection in these years  [1] . 
It is widely accepted that excessive cytokine production 
from macrophages and monocytes plays an important 
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 Abstract 
 Background/Aims: Cytokines play important roles in the 
pathophysiology of systemic infl ammatory response 
syndrome (SIRS) and sepsis. Therefore, some effective 
measures to remove cytokines from the bloodstream 
could be effective in the treatment of SIRS and sepsis. 
The aim of this study was to evaluate the cytokine ad-
sorptive property of various adsorbents for the purpose 
of the development of new selective cytokine adsorption 
columns.  Methods: The cytokine adsorptive property of 
adsorbent in a CF-X column, which consists of cellulose 
beads cross-linked with hexamethylene-di-isocyanate, 
was compared with those of various adsorbents in 
 currently  available  immunoadsorption  columns,  such 
 as Immusorba TR ® , Immusorba PH ® , Selesorb ® , and 
 Lixelle ® , in vitro batchwise test using patients’ plasma. 
A newly developed adsorbent, MPCF-X, which was mod-
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role in the pathophysiology of sepsis  [2, 3] . SIRS is a state 
in which excessive inﬂ ammatory cytokines are present in 
blood ﬂ ow, that is, hypercytokinemia. If SIRS becomes 
more serious or prolonged, circulating neutrophils and 
various mediator networks are activated, which leads to 
the development of organ dysfunction. Especially, proin-
ﬂ ammatory cytokines such as TNF-  , interleukin (IL)-
1  , IL-6 and IL-8 are considered to be closely related to 
the pathophysiology of sepsis and resulting organ dys-
function. In the last decade, so-called anti-cytokine im-
munotherapies using monoclonal antibodies, soluble re-
ceptors, and receptor antagonists against TNF-  and IL-
1  were aggressively studied for the treatment of sepsis 
 [4, 5] . Although these approaches showed satisfactory re-
sults in experiments on animals, results of clinical studies 
have been disappointing. Thus, the effective therapy 
against hypercytokinemia has not yet been established 
clinically  [6] . 
 Methods to remove cytokines from the bloodstream 
by means of blood puriﬁ cation have been under study 
mainly focusing on continuous renal replacement thera-
pies (CRRT) such as continuous hemoﬁ ltration (CHF) or 
continuous hemodiaﬁ ltration (CHDF)  [7] . However, the 
effects of these therapies are still controversial  [8, 9] . Re-
cent reports have indicated that adsorption to the hemo-
ﬁ lter membrane, rather than convection or diffusion, 
plays an important role in the action mechanism of cyto-
kine removal by CHF or CHDF  [10, 11] . 
 On the other hand, adsorbents that selectively adsorb 
various pathologic substances have been developed re-
cently, and selective adsorption of pathologic substances 
by means of plasma adsorption or direct hemoperfusion 
(DHP), so-called immunoadsorption, has been widely ap-
plied in clinical settings  [12, 13] . If an adsorption column 
that can selectively remove cytokines could be developed, 
it would be a new modality for the treatment of SIRS and 
sepsis. The purpose of the present study is to evaluate the 
cytokine adsorptive properties of various adsorbents in 
immunoadsorption columns that have been in clinical 
use and those still under development, using plasma of 
patients in vitro, in order to develop new cytokine adsorp-
tion columns. In the preliminary experiment, adsorbent 
in CF-X which is developed for the treatment of immu-
nologic diseases  [14] has been revealed to have strong af-
ﬁ nity to various cytokines. Therefore, the cytokine ad-
sorptive property of CF-X was compared in vitro with 
other adsorbents in currently available immunoadsor-
bent columns. Furthermore, we developed a new adsor-
bent by modifying adsorbent of CF-X, and its adsorptive 
property was also evaluated. 
 Materials and Methods 
 Patients’ Plasma 
 Forty-milliliter blood samples for adsorption experiments were 
collected from 3 patients with septic shock admitted to our ICU on 
days 1 and 2, after obtaining their informed consent. One patient 
was suffering from septic shock caused by acute obstructive sup-
purative cholangitis, and the other 2 patients developed septic 
shock due to panperitonitis caused by perforation of the digestive 
tract. All of them were male and ages ranged from 71 to 83 years. 
Two of them died and 1 survived. The blood samples collected from 
Table 1. Adsorbents tested
Name of columns Manufacturer Adsorbent Main adsorbable
substances
carrier material ligand
CF-X Ube Industries
Ichihara, Japan
Cellulose beads Hexamethylene-
di-isocyanate
Anti-DNA antibody,
pemphigus antibody
Immusorba TR® Asahi Medical
Tokyo, Japan
Polyvinyl
alcohol gel
Tryptophan Anti-acetylcholine receptor
antibody, immune complex
Immusorba PH® Asahi Medical
Tokyo, Japan
Polyvinyl
alcohol gel
Phenylalanine Rheumatoid factor,
immune complex
Selesorb® Kaneka
Osaka, Japan
Cellulose beads Dextran sulfate Anti-DNA antibody,
anti-cardiolipin antibody
Lixelle® Kaneka
Osaka, Japan
Cellulose beads Hexadecyl 
alkyl chain
2-Microglobulin
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these patients were centrifuged immediately to collect plasma sam-
ples. The plasma samples were stored at –70  °  C until the use in ad-
sorption experiments. The present study was conducted with the 
approval of the ethical committee. 
 Adsorbents 
 Table 1 shows various adsorbents used in this experiment. 
These adsorbents have the property of selectively adsorbing target 
pathologic substances by means of electrostatic bonding or hydro-
phobic bonding, rather than biologic bonding such as antigen-an-
tibody interaction. 
 CF-X is an immunoadsorption column under clinical trial and 
the column contains an adsorbent in which cellulose beads are 
cross-linked with hexamethylene-di-isocyanate. The adsorbent in 
CF-X has been proven to selectively adsorb antibodies related to 
systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), 
and pemphigus vulgaris  [14] . Among other adsorbents tested, the 
adsorbent in Immusorba TR ®  is targeted to adsorb anti-acetylcho-
line receptor antibody and immune complexes, and is used for the 
treatment of myasthenia gravis and Guillain-Barré syndrome  [15] . 
The adsorbent in Immusorba PH ®  adsorbs rheumatoid factor and 
immune complexes applying to the treatment of SLE and RA  [15] . 
The adsorbent in Selesorb ®  can remove anti-DNA antibodies ef-
ﬁ ciently and is used for the treatment of SLE  [16] . Adsorbent in 
Lixelle ®  can adsorb    2 -microglobulin by DHP and is used for the 
treatment of dialysis-related amyloidosis  [17] . 
 A Newly Developed Adsorbent 
 The adsorbent in CF-X  has a strong afﬁ nity to various patho-
logic antibodies and immune complexes. However, as it also shows 
a strong afﬁ nity to immunoglobulin G (IgG), it has the disadvantage 
of adsorbing and removing normal IgG as well  [17] . Therefore, we 
developed a new adsorbent, MPCF-X, by coating the surface of 
CF-X with 2-methacryloyloxyethyl phosphorylcholine (MPC) co-
polymer  [18] , a coating material used to improve the biocompati-
bility in various artiﬁ cial devices, and studied its cytokine adsorp-
tive property ( ﬁ g. 1 ). Two types of adsorbents, MPCF-XM20 and 
MPCF-XN20, were developed according to the difference in den-
sity of MPC coating. 
 In vitro Batchwise Adsorption Test 
 Pooled patient’s plasma samples were mixed and divided into 
two to conduct two series of experiments on adsorptive property. 
In the experiment on adsorptive property, 4.5 ml of patient’s plas-
ma were added to 1.5 ml of adsorbent (volumetric ratio v/v = 3/1), 
and then the sample was stirred and incubated at 37  °  C for 60 min. 
Immediately afterwards, the sample was centrifuged at 1,000 rpm 
for 2 min to collect its supernatant. Each of the experiments on 
adsorptive property was conducted in duplicate. 
 The total protein (TP), albumin (Alb), IgG, Na, and cytokine in 
plasma were measured both before and after adsorption (pre- and 
post-adsorption). Cytokines TNF-  , IL-1  , IL-6, and IL-10 were 
measured using a Medgenix EASIA kit (Biosource Europe SA, Fleu-
rus, Belgium), and IL-8 was measured using an IL-8 ELISA kit 
Water
CF-X
HMDI
Urethane bond
Cellulose
IgG
MPCF-X
MPC polymer
 Fig. 1. Schematic drawings of CF-X and a newly devel-
oped adsorbent, MPCF-X. IgG = Immunoglobulin G; 
HMDI = hexamethylene-di-isocyanate; MPC = 2-meth-
acryloyloxyethyl phosphorylcholine polymer. 
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(Toray Fuji Bionics, Tokyo, Japan). The corrected adsorption rate 
(Rc) of cytokines was calculated by using Na concentrations in the 
following formula: 
 Rc [%] = 
(1 – C (post)  ! C (Na-pre)/C (pre)  ! C (Na-post))  ! 100 
 Statistics 
 Data are presented as mean  8 SD. Comparison of corrected 
adsorption rate among various adsorbents was performed by one-
way analysis of variance with post-hoc test using Fisher’s PLSD. 
 p  ! 0.05 is considered signiﬁ cant. 
 Results 
 The  levels  of  TP,  Alb,  IgG,  Na,  TNF,  IL-1  , IL-6, 
 IL-8, and IL-10 in plasma were as shown in  table 2 . Be-
cause the level of IL-1  in plasma was below the mini-
mum detectable concentration (2 pg/ml), it was ruled out 
of the study. 
 Figure 2 shows the corrected adsorption rate of each 
adsorbent. There were signiﬁ cant differences in adsorp-
tive property among the adsorbents (p  ! 0.05). The ad-
sorption rate of TNF-  with the adsorbent in CF-X was 
100% and it was signiﬁ cantly higher than other adsor-
bents (p  ! 0.05). The adsorption rate of IL-6 was 98.9% 
with the adsorbent in CF-X  and was 72.0% with the ad-
sorbent in Lixelle ® . The adsorbent in CF-X showed sig-
niﬁ cantly higher adsorption rate than other adsorbents 
 (p  ! 0.05). Adsorption rate of IL-8 was highest with the 
adsorbent in Lixelle ®  and was more than 70% in all oth-
er adsorbents. IL-10 was well adsorbed with the adsor-
bent in CF-X  or Selesorb ® , adsorption rates were 88.7 and 
83.7%, respectively. These two adsorbents showed sig-
niﬁ cantly higher adsorption rates than other three adsor-
Table 2. Plasma concentrations of total protein (TP), albumin (Alb), immunoglobulin G (IgG), Na, and cyto-
kines
Experimental
plasma
TP
g/dl
Alb
mg/dl
IgG
mg/dl
Na
mEq/l
TNF-
pg/ml
IL-1
pg/ml
IL-6
pg/ml
IL-8
pg/ml
IL-10
pg/ml
No. 1 5.2 2,780 1,240 142 36.4 1.1 1,562 207 41
No. 2 4.2 2,080 1,080 143 58 1.7 6,025 299 28
TNF = Tumor necrosis factor; IL = interleukin.
 Fig. 2. In vitro cytokine adsorptive proper-
ties of various adsorbents. TNF = Tumor 
necrosis factor; IL = interleukin.  # p  ! 0.05 
compared to the other four columns; *p  ! 
0.05 compared to adsorbents in Immunsor-
ba TR ® , PH ® , and Lixelle ® . 
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bents (p  ! 0.05). In conclusion, the adsorbent in CF-X 
showed most remarkable adsorptive property for various 
cytokines and the adsorbent in Lixelle ®  followed. 
 Figure 3 shows the adsorptive property of newly de-
veloped adsorbent, MPCF-X. The adsorption rate of IgG 
was as high as 75.5% with the adsorbent in CF-X, while 
the rate decreased to 23.0 and 0% in MPCF-XM20 and 
MPCF-XN20, respectively. The adsorption rates of cyto-
kines such as IL-6, IL-8, and IL-10 with MPCF-XM20 or 
MPCF-XN20 slightly decreased compared to the adsor-
bent in CF-X. However, it became apparent that they 
could adsorb TNF-  almost completely. 
 Discussion 
 Since Bellomo et al.  [19] reported that cytokines could 
be removed by means of continuous veno-venous hemo-
ﬁ ltration, attempts to treat sepsis by CRRT have been 
made energetically  [7–10] . Considering that the molecu-
lar weights of cytokines are relatively high ranging from 
8,000 of IL-8 to 45,000 or 55,000 of a trimer of TNF-  , 
cytokines are considered to be removed mainly due to the 
principle of convection. However, the efﬁ ciency of re-
moving cytokines by CRRT is lower than the natural 
clearance in vivo and not high enough to decrease the 
blood levels, whereby its clinical efﬁ cacy has been contro-
versial  [8, 9] . We have reported that CHDF using a poly-
methylmethacrylate (PMMA) membrane hemoﬁ lter can 
remove various humoral mediators including cytokines 
by means of the principle of adsorption and that it is ef-
fective in treating septic multiple organ failure and severe 
acute pancreatitis  [11, 20] . This property is characteristic 
only in PMMA membrane, and was not observed with 
other membrane material, such as ethylene vinyl alcohol, 
polyacrylonitrile, or polysulfone. De Vriese et al.  [10] also 
reported that the removal of cytokines by CHF using AN-
69 hemoﬁ lter was mainly due to adsorption to a hemoﬁ l-
ter membrane. 
 Recently, the hemodynamic effect of high-volume he-
moﬁ ltration in which 6 l/h of ﬁ ltrate was removed to en-
hance removal of cytokines and other mediators has been 
reported  [21] . However, high blood ﬂ ow rate (300 ml/h) 
is necessary to obtain a large volume of ﬁ ltrate in high-
volume hemoﬁ ltration. This is impractical, even at risk 
for hemodynamically unstable patients, such as septic 
shock. Meanwhile, it has been reported that the adsorp-
tive resin was capable of signiﬁ cantly removing middle 
molecular weight substances including various cytokines 
 [22] . Ronco et al.  [23] developed and reported the con-
tinuous plasma ﬁ ltration adsorption, a combination of 
plasma ﬁ ltration and adsorption by resin. Thus, sorbent 
adsorption of cytokines has been paid attention to re-
cently  [24–26] . 
 If a column that can selectively adsorb and remove 
cytokines in blood by means of DHP could be developed, 
it can be a new treatment technique for SIRS and sepsis. 
Recently, we discovered that adsorbent in CF-X, an im-
munoadsorbent column which has a strong afﬁ nity to 
various antibodies and has been under clinical trial for 
the treatment of SLE, RA and pemphigus vulgaris, had 
strong afﬁ nity to various cytokines. Therefore, in the 
 Fig. 3. Adsorptive properties of newly de-
veloped cytokine adsorbents, MPCF-XM20 
and MPCF-XN20. TNF = Tumor necro -
sis factor; IL = interleukin; Alb = albumin;
IgG = immunoglobulin G. 
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